Alzheon, a Phase 3 biotech developing small molecule therapies for Alzheimer's disease, announced terms for its IPO on Tuesday.
The Framingham, MA-based company plans to raise $35 million by offering 2.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Alzheon would command a fully diluted market value of $196 million.
Alzheon was founded in 2013 and plans to list on the Nasdaq under the symbol ALZH. ThinkEquity and H.C. Wainwright are the joint bookrunners on the deal. IPO timing was not announced.
